The U.S. Supreme Court's ruling in Mayo Collaborative Services et al. v. Prometheus Laboratories Inc. did little to remove uncertainty about what molecular diagnostic claims are patentable under Section 101 of the Patent Act.

By a 9-0 vote last week, the high court struck down Prometheus' diagnostic patents but gave no guidance on what would have made the claims patentable.